Bluefin Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bluefin Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-17,400	Closed	-$15K	–	1011
2021 Q2	$15K	Buy	+17,400	New	+$2.99M	﹤0.01%	578
2020 Q2	–	Sell	-30,000	Closed	-$192K	–	509
2020 Q1	$192K	Buy	+30,000	New	+$2.94M	0.02%	255
2018 Q2	–	Sell	-98,500	Closed	-$882K	–	529
2018 Q1	$882K	Buy	+98,500	New	+$11.8M	0.06%	159

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Bluefin Capital Management's ALXN Position: Q2 2021 in Review

Bluefin Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 8,837 shares — an estimated $1.52M sold.

Bluefin Capital Management first reported a position in ALXN in Q1 2018 and held it in 3 quarters. The position peaked at $6.31M in Q1 2018. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Bluefin Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Bluefin Capital Management sold 8,837 Alexion Pharmaceuticals shares in Q2 2021, an estimated $1.52M.
Bluefin Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Bluefin Capital Management's Alexion Pharmaceuticals position peaked at $6.31M in Q1 2018.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Bluefin Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.